Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T16:57:39.213Z.
Calculation as of: 2026-10-06T16:57:39.213Z.
Quote observation: 2026-10-06T16:55:05.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5f972cfcdde9e4531ce3198b66662ffcb9080d57c966754dbe52ec7edaf14096
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
NervGen Pharma Corp. Common stock
Market Cap
$149.18M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$148.31M
EV/EBITDA Ratio
N/A
TTM Avg
159.13x
3Y Avg
159.13x
5Y Avg
159.13x
Market Cap
$146.88M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$146.98M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$151.65M
EV/EBITDA Ratio
N/A
TTM Avg
183.85x
3Y Avg
184.46x
5Y Avg
184.46x
Market Cap
$151.58M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$152.73M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$144.84M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NervGen Pharma Corp. Common stock (NGEN) | $149.18M | N/A | N/A | N/A | N/A |
| LifeMD, Inc. (LFMDP)vs › | $148.31M | N/A | 159.13x | 159.13x | 159.13x |
| Anavex Life Sciences Corp. (AVXL)vs › | $146.88M | N/A | N/A | N/A | N/A |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.98M | N/A | N/A | N/A | N/A |
| Codexis, Inc. (CDXS)vs › | $151.65M | N/A | 183.85x | 184.46x | 184.46x |
| Cardiol Therapeutics Inc. (CRDL)vs › | $151.58M | N/A | N/A | N/A | N/A |
| ALX Oncology Holdings Inc. (ALXO)vs › | $152.73M | N/A | N/A | N/A | N/A |
| Korsana Biosciences, Inc. (KRSA)vs › | $144.84M | N/A | N/A | N/A | N/A |
| Nyxoah S.A. (NYXH)vs › | $144.10M | N/A | N/A | N/A | N/A |
| Immuneering Corporation (IMRX)vs › | $142.85M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
